All stock lists
Kyntra Bio, Inc. (NASDAQ:KYNB)
US · Delayed Price · Currency is USD
Also listed: 0IL8.L, FGENHealthcare · Biotechnology
4.41-0.17 (-3.71%)
Insider Score
––Not scored
KYNB Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
KYNB Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | -1.47 M | 3.74 M | 1.28 M | 1.08 M | 1.35 M | 2.74 M |
| Revenue Growth (YoY) | -209.35 % | 36.47 % | 101.04 % | -97.68 % | 35.07 % | -89.20 % |
| Cost of Revenue | 2.00 K | 4.11 M | -463.00 K | 134.00 K | 306.00 K | 579.00 K |
| Gross Profit | -1.48 M | -368.00 K | 1.74 M | 942.00 K | 1.04 M | 2.16 M |
| SG&A Expense | 9.27 M | 5.86 M | 7.99 M | 5.10 M | 6.84 M | 7.78 M |
| R&D Expense | 6.82 M | 7.57 M | 7.27 M | 1.21 M | 5.87 M | 9.18 M |
| Operating Expenses | 16.10 M | 13.45 M | 15.81 M | 6.31 M | 12.70 M | 16.95 M |
| Operating Income | -17.57 M | -13.82 M | -14.07 M | -5.37 M | -11.66 M | -14.79 M |
| Pretax Income | 11.97 M | -15.13 M | -14.61 M | -13.15 M | -13.78 M | -16.76 M |
| Tax Provision | -1.00 K | 0.00 | 0.00 | 0.00 | -92.00 K | 2.00 K |
| Net Income | 11.97 M | -15.20 M | 37.94 M | 148.47 M | -7.60 M | 4.64 M |
| EPS (Basic) | 2.96 | -3.76 | 9.38 | 49.61 | -1.88 | 0.05 |
| EPS (Diluted) | 2.96 | -3.76 | 9.38 | 49.61 | -1.88 | 0.05 |
| Shares Outstanding | 4.05 M | 4.05 M | 4.04 M | 4.04 M | 4.04 M | 4.04 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.